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hospital in Austria for the last two months of life of cancer
patients. METHODS:Two groups of cancer patients, who had at
least one stay in the inpatient palliative care unit, were formed
retrospectively. All patients died in 2005 or 2006. Patients in the
control group “no home care support team—NHCST” only got
inpatient care. Patients in the intervention group “home care
support teams—HCST” got additional home care support.
Patients of NHCST and HCST were matched by age, sex and
main diagnosis to ensure that patients in both groups were com-
parable (N = 60 for each group). Only public health care expen-
ditures were considered. Data comprised of the Minimum Basic
Data Set from all public hospitals in Styria and the follow-up
costs dataset from the largest compulsory health insurance insti-
tution of Styria. Health care expenditures were allocated to costs
for inpatient care, costs for outpatient care (general medicine,
specialized medicine, drugs, assistive technology, costs of trans-
port), and costs of home care support teams. Finally, health care
expenditures of the last two months of life were compared for
both groups. RESULTS: Mean costs for inpatient care of
NHCST/HCST are €7502/€5843 (€1659/22.1% /p = 0.035).
Mean costs for outpatient care of NHCST/HCST are €1106/
€1391 (€ + 285 / + 25.8% / p = 0.063). The mean costs for home
care support teams are €1290 for HCST group. Total health care
costs are almost the same for both groups (HCST: €8524 vs.
NHCST: €8608 /€ + 84 / + 1% / p = 0.988). CONCLUSIONS:
HCST shows tendency of being self-ﬁnancing due to savings of
inpatient care for the last two months of life of cancer patients.
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OBJECTIVES: Opioids comprise the main option in the man-
agement of moderate-to-severe cancer pain. Different opioids are
used in rotation to eliminate tolerance and opioid side effects that
limit increasing dose. Since there are only two non-parenteral
opioids—morphine and fentanyl—in Turkey, pain control with
rotation might not be successfully done and invasive treatment
modalities are to be selected much earlier than optimal. The aim
of the study is to evaluate the contribution of the addition of a
new long-acting oral opioid (OROS hydromorphone) into the
current opioid market, with regard to the cost of treatment in
moderate-to-severe cancer pain. METHODS: Model: Decision
tree modeling to compare the current two-opioid-market with
the hypothetical three-opioid-market, is used in the calculation of
costs. Patients are treated with rotation of two and three opioids
in the current and hypothetical market respectively. Time horizon
is eight weeks. The study has been performed from the health
care payer perspective. Data sources: The clinical data are
acquired from the literature. Prices of medications, discount
rates, other costs related to the treatment are obtained from
Ministry of Health Drug Price List, Price List of Social Security
Institution Health Implementation Guideline Appendix 2/D and
8, respectively. Analysis: Direct medical costs that are considered
are the costs of opioids, invasive treatment modalities, side
effects, physician visits and hospitalization. Because time horizon
is shorter than 1 year, costs are not discounted. The results are
presented as total costs of alternatives. RESULTS: Costs of
treatment are calculated as €1528/patient for the current two-
opioid-market and €1070€/patient for hypothetical three-opioid-
market. The amount of saving is €458/patient. CONCLUSIONS:
Inclusion of OROS hydromorphine into the Turkish market will
both increase the chance of patients be treated with non-
parenteral opioids without need to non-invasive methods and
also provide saving in the total medical costs of treatment.
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OBJECTIVES: Particle therapy (PT) with protons or carbon-
ions appears more effective in cancer treatment than conven-
tional treatment with photons. The investment costs are
however much higher. For a reliable estimate of the cost-
effectiveness of particle therapy an objective cost estimate is
crucial. Therefore, an extensive cost analysis was performed for
each facility. METHODS: An analytical framework with all rel-
evant parameters based on literature review and expert opinion
was built in Excel. Costs were calculated for: (A) combined
carbon-ion and proton facility (B) proton-facility, (C) photon-
facility. The total costs per year were calculated as the sum of the
capital costs divided by the life cycle of the facility (30 years) and
the running costs per year. The cost per fraction was calculated
as total costs per year divided by number of fractions per year.
The number of fractions per year was calculated in an opera-
tional model. RESULTS: The capital costs per facility are: (A)
€138.6 m, (B) €94.9 m, (C) €23,4 m. The annual running costs
are: (A) €21 m, (B) €14.2 m (C) 6,9 m. The costs per fraction per
facility are: (A) €787, (B) €516, (C) €187. The cost ratio is 4.2
for the combined-facility vs photon-facility and 2.8 for the
proton-facility vs photon-facility. The incremental costs are €600
and €329 per fraction, respectively. The costs per fraction for (C)
increased to 543€ when special treatment category tumors only
were included. A 20% variation in the annual number of frac-
tions, capital costs and running costs, resulted in changes in the
cost per fraction from -17% to +25%. The number of fractions
caused the biggest change, the capital costs the smallest. CON-
CLUSIONS: A combined carbon-ion/proton facility is the most
costly facility, followed by a proton facility. The outcomes are
most sensitive for the patient throughput, patient mix, and
average time per fraction.
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OBJECTIVES: To compare costs and outcomes of alemtuzumab
and chlorambucil as ﬁrst line treatment for patients with high-risk
(17p-) chronic lymphocytic leukemia (CLL) in the UK.
METHODS: A lifetime Markov model was developed. Patients
were modeled receiving treatment and moving through post-
treatment response and progressive disease. Three possible lines of
chemotherapy were considered, followed by ﬁnal disease progres-
sion and death. Patients had CLL, were chemotherapy naïve and
exhibited deletion of the chromosome 17p, a defect associated
with poor prognosis and failure to respond to other CLL thera-
pies. Response rate and duration at ﬁrst line were taken from a
recent randomized study, the CAM307 trial, for subsequent lines
A480 Abstracts
